Previous close | 147.37 |
Open | 150.11 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 146.93 - 147.40 |
52-week range | 146.93 - 147.40 |
Volume | |
Avg. volume | N/A |
Market cap | 2.191B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 0.21 |
EPS (TTM) | 6.97 |
Earnings date | 26 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
I’m searching far and wide to find the best dividend stocks that money can buy. Do the Americans have more to offer when it comes to value investing? The post 3 top US dividend stocks for value investors to consider in 2024 appeared first on The Motley Fool UK.
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime